109PDOVERALL SURVIVAL (OS) WITH AFATINIB (A) VS CHEMOTHERAPY (CT) IN PATIENTS (PTS) WITH NSCLC HARBOURING EGFR MUTATIONS (MUT): SUBGROUP ANALYSES BY RACE IN LUX-LUNG 3 (LL3) AND LUX-LUNG 6 (LL6)


    loading  Checking for direct PDF access through Ovid

Abstract

Abstract unavailable for this article.


    loading  Loading Related Articles